Allergy Department, Virgen del Camino Hospital, Pamplona, Spain.
Ann Allergy Asthma Immunol. 2011 Jul;107(1):35-41. doi: 10.1016/j.anai.2011.03.017. Epub 2011 Apr 30.
Component-resolved diagnostics (CRD) has recently been introduced into clinical allergology.
The aim of this study was to assess the contribution that this new diagnostic technique makes to conventional diagnosis in patients with pollen allergy, comparing CRD with conventional technologies, and to compare 2 CRD methods, Advia-Centaur and Microarray-ISAC.
Serum samples from 120 pollen-allergic patients were obtained. Immunoglobulin (Ig) E to total extracts (CAP System) and individual allergens using both CRD methods were determined.
The 3 diagnostic methods were in agreement in 62.5% of cases. In 30%, the CRD modified the conventional diagnosis either by detecting new relevant sensitizations (mainly to Olea) or by ruling out clinically irrelevant sensitizations caused by panallergens. The main differences between the 2 CRD methods were the deficiency in the ISAC version we used (ISAC-CRD-89) to detect sensitizations to Salsola and Plantago and that Advia-Centaur did not detect sensitizations to cypress. For all allergens except for Par j 1, a significant association in the frequency of sensitization was seen with the 2 CRD techniques and good agreement when comparing the results of the 2 methods in all cases. Significant correlation was found in the concentration of specific IgE in the 2 techniques for the most prevalent allergens in our setting. The results of the different profilins analyzed using Microarray-ISAC were superimposable although somewhat lower in the case of Phl p 12.
Component-resolved diagnostics modified the conventional diagnosis in 30% of cases. The results from the 2 CRD methods showed good agreement and correlation for most allergens.
组分分辨诊断(CRD)最近已被引入临床变态反应学。
本研究旨在评估该新技术在花粉过敏患者中的常规诊断中的作用,比较 CRD 与传统技术,并比较 2 种 CRD 方法,即 Advia-Centaur 和 Microarray-ISAC。
收集 120 例花粉过敏患者的血清样本。使用两种 CRD 方法分别测定总提取物(CAP 系统)和个体过敏原的免疫球蛋白 E(IgE)。
三种诊断方法的符合率为 62.5%。在 30%的病例中,CRD 通过检测新的相关致敏原(主要是橄榄)或排除由泛过敏原引起的临床无关致敏原来改变常规诊断。两种 CRD 方法之间的主要区别在于我们使用的 ISAC 版本(ISAC-CRD-89)检测到对 Salsola 和 Plantago 的致敏原的不足,以及 Advia-Centaur 未检测到对柏树的致敏原。除了 Par j 1 之外,对于所有过敏原,我们都观察到两种 CRD 技术的致敏频率存在显著相关性,并且在比较两种方法的所有结果时,一致性良好。在我们的研究中,对于大多数流行的过敏原,在两种技术中都发现了特异性 IgE 浓度的显著相关性。尽管在 Phl p 12 的情况下,使用 Microarray-ISAC 分析的不同丝氨酸蛋白酶抑制剂的结果有些低,但它们是可叠加的。
CRD 在 30%的病例中改变了常规诊断。两种 CRD 方法的结果对于大多数过敏原具有良好的一致性和相关性。